Profile data is unavailable for this security.
About the company
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of pharmaceutical products. The Company is also engaged in the research and development, marketing and distribution of pharmaceuticals. The products of the Company include anti-viral drugs, endocrine and metabolic drugs and cardiovascular drugs. Its main products include Kewei, Ertongshu, Oumeining, Xinhaining and Xining.
- Revenue in HKD (TTM)6.81bn
- Net income in HKD2.16bn
- Incorporated2001
- Employees4.62k
- LocationYiChang HEC ChangJiang Pharmaceutical Co LtdZhen An Road No. 368Shangsha Village, Chang'an TownDONGGUAN 443300ChinaCHN
- Phone+86 76 981768866
- Fax+86 76 981768866
- Websitehttp://www.hec-changjiang.com/
More ▼
Mergers & acquisitions
| Acquired company | 1558:HKG since announced | Transaction value |
|---|---|---|
| Dongguan Hec Taigen Biopharmaceuticals Co Ltd | 33.73% | 4.98m |
Data delayed at least 15 minutes, as of May 17 2024 09:08 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Fudan-Zhangjiang Bio-Pharm. Co | 875.44m | 110.55m | 6.50bn | 948.00 | 20.67 | 0.9014 | -- | 7.43 | 0.1074 | 0.1074 | 0.8314 | 2.46 | 0.2852 | 1.44 | 1.62 | 923,457.40 | 3.59 | 7.03 | 4.35 | 9.05 | 91.40 | 92.17 | 12.59 | 17.26 | 3.94 | 568.37 | 0.0062 | 39.16 | -17.50 | 2.78 | -21.28 | -0.6326 | 20.49 | 0.00 |
| Tong Ren Tang Technologies Co Ltd | 7.33bn | 638.47m | 7.42bn | 4.10k | 11.61 | 0.995 | 5.40 | 1.01 | 0.4985 | 0.4985 | 5.72 | 5.82 | 0.5212 | 0.9835 | 5.68 | 1,786,787.00 | 7.64 | 7.68 | 12.10 | 12.32 | 42.04 | 43.50 | 14.65 | 16.11 | 2.37 | -- | 0.1443 | 39.94 | 13.04 | 6.01 | 1.25 | -2.73 | -22.26 | 0.0178 |
| China Shineway Pharmaceutical Group Ltd | 4.89bn | 1.05bn | 7.83bn | 3.44k | 6.82 | 1.03 | 6.38 | 1.60 | 1.39 | 1.39 | 6.47 | 9.20 | 0.5073 | 1.44 | 6.31 | 1,422,015.00 | 10.89 | 8.03 | 14.15 | 9.77 | 75.15 | 74.55 | 21.47 | 17.87 | 2.98 | -- | 0.0411 | 36.29 | 14.32 | 11.94 | 34.14 | 13.89 | 0.6396 | 12.88 |
| Everest Medicines Ltd | 136.23m | -913.55m | 7.91bn | 432.00 | -- | 1.45 | -- | 58.04 | -2.92 | -2.92 | 0.4352 | 16.83 | 0.0203 | 2.25 | 4.57 | 315,358.20 | -13.63 | -30.52 | -15.06 | -33.14 | 72.67 | -- | -670.57 | -5,745.25 | 8.29 | -- | 0.0979 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| Beijing Tong Ren Tang Chinese Medicine | 1.52bn | 540.39m | 8.71bn | 798.00 | 16.11 | 2.25 | 12.93 | 5.71 | 0.6456 | 0.6456 | 1.82 | 4.62 | 0.3522 | 0.6449 | 2.31 | 1,910,959.00 | 13.64 | 16.71 | 15.50 | 18.75 | 68.67 | 69.88 | 38.73 | 40.72 | 8.59 | -- | 0.0317 | 68.87 | -11.91 | 0.1459 | -16.33 | -1.43 | -16.30 | 7.49 |
| Lepu Biopharma Co Ltd | 243.79m | -23.90m | 8.75bn | 429.00 | -- | 9.01 | 112.08 | 35.87 | -0.0144 | -0.0144 | 0.1469 | 0.5847 | 0.0917 | 1.06 | 1.62 | 568,271.50 | -1.23 | -- | -1.91 | -- | 87.45 | -- | -13.45 | -- | 0.7201 | 0.1388 | 0.4549 | -- | 1,347.16 | -- | 96.79 | -- | -- | -- |
| Cansino Biologics Inc | 373.42m | -1.60bn | 9.25bn | 1.49k | -- | 0.9243 | -- | 24.76 | -6.50 | -6.50 | 1.51 | 23.10 | 0.0332 | 2.37 | 0.4619 | 249,947.80 | -18.93 | -4.27 | -26.69 | -5.60 | -253.78 | -- | -569.97 | -27.72 | 1.86 | -- | 0.3381 | -- | -66.52 | 213.94 | -63.04 | -- | 30.60 | -- |
| AIM Vaccine Co Ltd | 1.28bn | -1.41bn | 9.72bn | 1.62k | -- | 2.47 | -- | 7.57 | -1.16 | -1.16 | 1.06 | 3.25 | -- | -- | -- | 791,020.30 | -- | -- | -- | -- | 75.88 | -- | -164.24 | -- | 0.7583 | -14.04 | 0.3158 | -- | -6.06 | -- | -307.07 | -- | -- | -- |
| InnoCare Pharma Ltd | 798.96m | -682.91m | 9.79bn | 1.09k | -- | 1.14 | -- | 12.25 | -0.4049 | -0.4049 | 0.4735 | 4.39 | 0.073 | 1.39 | 3.39 | 733,662.20 | -6.38 | -13.41 | -8.08 | -15.36 | 82.61 | 85.99 | -87.42 | -172.16 | 4.13 | -- | 0.1582 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
| Shanghai Henlius Biotech Inc | 5.84bn | 590.69m | 9.89bn | 3.64k | 16.79 | 4.17 | 10.10 | 1.69 | 1.08 | 1.08 | 10.69 | 4.36 | 0.5731 | 1.95 | 9.10 | 1,604,695.00 | 5.80 | -8.59 | 12.47 | -14.14 | 72.64 | 71.77 | 10.12 | -27.37 | 0.3786 | 6.48 | 0.6512 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 6.81bn | 2.16bn | 10.40bn | 4.62k | 4.83 | 1.21 | 4.28 | 1.53 | 2.45 | 2.45 | 7.74 | 9.76 | 0.5111 | 3.62 | 4.09 | 1,474,568.00 | 15.07 | 8.03 | 24.46 | 11.81 | 79.21 | 79.97 | 29.48 | 20.80 | 1.30 | 11.16 | 0.2475 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
| Keymed Biosciences Inc | 383.06m | -388.76m | 10.64bn | 897.00 | -- | 3.29 | -- | 27.79 | -1.49 | -1.49 | 1.45 | 11.55 | 0.0906 | 0.7314 | 26.14 | 427,050.40 | -9.16 | -- | -10.05 | -- | 89.59 | -- | -101.04 | -- | 9.18 | -- | 0.123 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| Luye Pharma Group Ltd | 6.65bn | 576.18m | 11.17bn | 5.27k | 19.29 | 0.8241 | 8.32 | 1.68 | 0.1539 | 0.1539 | 1.78 | 3.60 | 0.247 | 2.42 | 3.60 | 1,261,035.00 | 2.17 | 2.80 | 3.56 | 4.45 | 68.44 | 70.53 | 8.78 | 10.39 | 1.21 | 3.10 | 0.3931 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| SciClone Pharmaceuticals (Holdings) Ltd | 3.41bn | 1.21bn | 11.47bn | 1.05k | 9.79 | 3.12 | 8.36 | 3.36 | 1.86 | 1.86 | 5.25 | 5.85 | 0.7585 | 3.56 | 3.83 | 3,251,220.00 | 26.97 | 27.09 | 33.34 | 36.32 | 74.67 | 76.06 | 35.55 | 35.43 | 4.50 | 33.70 | 0.01 | 22.98 | 14.76 | 17.50 | 31.16 | 15.96 | 25.65 | -- |
Data as of May 17 2024. Currency figures normalised to YiChang HEC ChangJiang Pharmaceutical Co Ltd's reporting currency: Hong Kong Dollar HKD
4.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 15.73m | 2.41% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 5.78m | 0.88% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.98m | 0.46% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 1.33m | 0.20% |
| BlackRock Advisors (UK) Ltd.as of 02 Apr 2024 | 846.40k | 0.13% |
| American Century Investment Management, Inc.as of 04 Apr 2024 | 737.40k | 0.11% |
| Schroder Investment Management North America, Inc.as of 28 Feb 2021 | 449.60k | 0.07% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 424.60k | 0.07% |
| Generation Investment Management LLPas of 31 Dec 2019 | 380.80k | 0.06% |
| AXA Investment Managers UK Ltd.as of 28 Mar 2024 | 376.40k | 0.06% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
